Literature DB >> 11973011

Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial.

Diana D Cardenas1, Catherine A Warms, Judith A Turner, Helen Marshall, Marvin M Brooke, John D Loeser.   

Abstract

Chronic pain in persons with spinal cord injury (SCI) is a difficult problem for which there is no simple method of treatment. Few randomized controlled trials of medications for pain in persons with SCI have been conducted. This study was designed to determine whether amitriptyline, a tricyclic antidepressant, is efficacious in relieving chronic pain and improving pain-related physical and psychosocial dysfunction in persons with SCI. Eighty-four participants with SCI and chronic pain were randomized to a 6-week trial of amitriptyline or an active placebo, benztropine mesylate. All pre- and post-treatment assessments were conducted by evaluators blind to the allocation. Regression analyses were conducted to examine whether there was a medication group effect on the primary (average pain intensity) and secondary outcome measures. No significant differences were found between the groups in pain intensity or pain-related disability post-treatment, in either intent-to-treat analyses or analyses of study completers. These findings do not support the use of amitriptyline in the treatment of chronic pain in this population, but we cannot rule out the possibility that certain subgroups may benefit.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973011     DOI: 10.1016/S0304-3959(01)00483-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  50 in total

1.  Evaluating the effectiveness of antidepressant therapy adjuvant to gabapentin and pregabalin for treatment of SCI-related neuropathic pain.

Authors:  Emily Carol McKinley; Elizabeth J Richardson; Gerald McGwin; Jie Zhang
Journal:  J Spinal Cord Med       Date:  2018-01-10       Impact factor: 1.985

Review 2.  Neuropathic Pain After Spinal Cord Injury: Challenges and Research Perspectives.

Authors:  Rani Shiao; Corinne A Lee-Kubli
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 3.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 4.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

Review 6.  Rehabilitation and treatment of spinal cord tumors.

Authors:  Vishwa S Raj; Latanya Lofton
Journal:  J Spinal Cord Med       Date:  2013-01       Impact factor: 1.985

7.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

8.  Effectiveness of amitriptyline and lamotrigine in traumatic spinal cord injury-induced neuropathic pain: a randomized longitudinal comparative study.

Authors:  N Agarwal; M Joshi
Journal:  Spinal Cord       Date:  2016-08-16       Impact factor: 2.772

Review 9.  An evidence-based algorithm for the treatment of neuropathic pain.

Authors:  Nanna B Finnerup; Marit Otto; Troels S Jensen; Søren H Sindrup
Journal:  MedGenMed       Date:  2007-05-15

10.  Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial.

Authors:  Dennis C Ang; Mark P Jensen; Jennifer L Steiner; Janna Hilligoss; Richard H Gracely; Chandan Saha
Journal:  Clin J Pain       Date:  2013-09       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.